Real-World Use of Talimogene Laherparepvec in German Patients with Stage IIIB to IVM1a Melanoma: A Retrospective Chart Review and Physician Survey.

ABSTRACT:

Introduction

Talimogene laherparepvec is a first-in-class oncolytic immunotherapy for intratumoral injection with proven efficacy and tolerability in patients with unresectable early metastatic melanoma (stage IIIB-IVM1a) in the pivotal phase III OPTiM study. The objective was to characterize melanoma patients treated with talimogene laherparepvec in routine clinical practice in Germany.

Methods

A retrospective chart review was conducted in unresectable stage IIIB-IVM1a melanoma patients. Data on demographics, disease and medical history, and use of talimogene laherparepvec were collected. A survey was also conducted to understand physician treatment decisions.

Results

Data for 27 patients who initiated talimogene laherparepvec between June 2016 and July 2017 were ana

SUBMITTER: Mohr P 

PROVIDER: S-EPMC6318239 | biostudies-literature | 2019 Jan

REPOSITORIES: biostudies-literature